Bristol-Myers Squibb Co. (BMY) PT Raised to $94 at BMO Capital; 'Home Run for Deucra Labeling in Psoriasis'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman raised the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $94.00 while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
